Point72 Asset Management L.P. raised its position in Qiagen (NYSE:QGEN - Free Report) by 170.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 125,646 shares of the company's stock after buying an additional 79,207 shares during the quarter. Point72 Asset Management L.P. owned about 0.06% of Qiagen worth $5,595,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Brown Brothers Harriman & Co. bought a new stake in shares of Qiagen during the 4th quarter valued at approximately $37,000. Geneos Wealth Management Inc. grew its holdings in shares of Qiagen by 41.5% during the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after purchasing an additional 526 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after purchasing an additional 835 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Qiagen by 83.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company's stock valued at $70,000 after purchasing an additional 712 shares during the last quarter. 70.00% of the stock is owned by institutional investors.
Analysts Set New Price Targets
QGEN has been the topic of several research reports. Robert W. Baird lifted their price target on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. StockNews.com raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Baird R W downgraded shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Finally, UBS Group cut their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $48.42.
View Our Latest Stock Analysis on Qiagen
Qiagen Stock Up 0.3%
NYSE:QGEN opened at $42.77 on Tuesday. The firm's 50 day simple moving average is $41.03 and its 200 day simple moving average is $41.82. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. Qiagen has a one year low of $37.63 and a one year high of $49.30. The company has a market cap of $9.51 billion, a PE ratio of 119.09, a P/E/G ratio of 2.39 and a beta of 0.67.
Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company's revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.44 EPS. On average, research analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.
Qiagen Company Profile
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
